Single Dose Oral Bioequivalence Study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets
Phase 1
Completed
- Conditions
- Major Depressive Disorder (MDD)
- Interventions
- First Posted Date
- 2022-06-14
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- Seasons Biotechnology (Taizhou) Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT05417087
- Locations
- 🇮🇳
Cliantha Research Limited, Ahmedabad, Gujarat, India
Food Effect Bioavailability Study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets
Phase 1
Completed
- Conditions
- Major Depressive Disorder (MDD)
- Interventions
- First Posted Date
- 2022-06-14
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- Seasons Biotechnology (Taizhou) Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05416957
- Locations
- 🇮🇳
Cliantha Research Limited, Ahmedabad, Gujarat, India
Single Dose Study to Evaluate Dose-proportionality of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets
Phase 1
Completed
- Conditions
- Major Depressive Disorder (MDD
- Interventions
- First Posted Date
- 2022-06-13
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- Seasons Biotechnology (Taizhou) Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT05416762
- Locations
- 🇮🇳
Cliantha Research Limited, Ahmedabad, Gujarat, India
© Copyright 2025. All Rights Reserved by MedPath